Source comparison
Tolerance to CJC-1295 Cycling: Evidence vs Manufacturer Claims Comparison
Continuous Use Viability '12+ weeks sustained efficacy' Receptor density ↓55% by week 4 (Eur J Endocrinol 2018) IGF-1 plateau observed 6–8 weeks in >70% of continuous protocols Tolerance is inevitable without cycling. Claims reflect product sales goals, not re
This comparison does not assign a generated winner or score.
- Continuous Use Viability
- '12+ weeks sustained efficacy'
- Receptor density ↓55% by week 4 (Eur J Endocrinol 2018)
- IGF-1 plateau observed 6–8 weeks in >70% of continuous protocols
- Tolerance is inevitable without cycling. Claims reflect product sales goals, not receptor biology
- Optimal Cycle Length
- 'Use until goals achieved'
- 1:1 on/off ratio maintains 85–95% receptor recovery (J Endocrinol 2019)
- 4-week cycles with equal washouts show consistent response across multiple cycles
- Evidence strongly supports structured periodicity over goal-based endpoints
- Dose Escalation Strategy
- 'Increase dose if response diminishes'
- Dose escalation accelerates desensitization without restoring efficacy (Endocrinology 2020)
- Higher doses during tolerance phase worsen subsequent cycle responsiveness
- Escalation is counterproductive. Early cycle termination outperforms dose increases 4/5
- Recovery Timeline
- '1–2 week breaks sufficient'
- Minimum 28 days required for receptor resynthesis (Mol Endocrinol 2017)
- Protocols with <3-week washouts show progressive decline across cycles
- Short breaks delay tolerance but do not prevent it. Minimum 4 weeks required
- Stacking with GHRPs
- 'No tolerance interaction'
- Separate receptor pathways allow complementary action without cross-tolerance (Peptides 2021)
- GHRP co-administration maintains additive GH response during CJC tolerance onset
- GHRPs are mechanistically independent but require their own cycling protocols